ALS biomarker study seeks clues in blood and spinal fluid
NCT ID NCT07260981
First seen Jan 02, 2026 · Last updated May 25, 2026 · Updated 20 times
Summary
This study looked at 60 people—ALS patients and healthy volunteers—to measure specific immune and nerve damage markers in their blood and spinal fluid. The goal was to better understand how the immune system's interferon-alpha pathway relates to ALS. Results may help identify patient subgroups and guide future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pioneer Life Sciences Cherrywood
Dublin, Ireland
Conditions
Explore the condition pages connected to this study.